EC Dental Science

Sinonasal glomangiopericytoma is an infrequently discerned, soft tissue neoplasm demonstrating differentiation akin to perivascular myoid cells. Tumefaction is pervaded with hemangiopericytoma-like vasculature. Previously designated as sinonasal type hemangiopericytoma, glomus tumour or intranasal myopericytoma, neoplasm is additionally denominated as glomangiopericytoma, sinonasal type.

Commonly, tumefaction is confined to nasal cavity and manifests with nasal obstruction, epistaxis or sinusitis. Neoplasm is accompanied by genomic mutation within CTNNB1 gene along with oncogenic activation of β catenin and immune reactivity to nuclear β catenin.

Singular surgical extermination of the neoplasm is accompanied by superior prognostic outcomes wherein proportionate tumour reoccurrence emerges at ~27%.

The exceptionally encountered sinonasal glomangiopericytoma comprises of < 0.5% of primary sinonasal neoplasms. Mean age of disease emergence is the 7^th decade whereas tumefaction may implicate paediatric subjects of ~5 years to elderly individuals of ~90 years.

1. Gordon AJ., et al. “Sinonasal Glomangiopericytoma with Prolonged Postsurgical Follow-Up”. Journal of Neurological Surgery Reports 3 (2022): e87-e89.
2. Moussaoui ZNE., et al. “Clinical and histopathological findings of a rare sinonasal glomangiopericytoma”. Autopsy and Case Reports 13 (2023): e2023424.
3. Almarri FK., et al. “A rare case of glomangiopericytoma in the nasal cavity: A case report in light of recent literature”. Annals of Medicine and Surgery 77 (2022): 103685.
4. Kazi AA., et al. “Glomangiopericytoma: a case series with review of literature”. Brazilian Journal of Otorhinolaryngology 5 (2022): 817-820.
5. Turri-Zanoni M., et al. “Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment”. Current Oncology Reports 1 (2022): 55-67.
6. Image 1 Courtesy: Science direct.
7. Image 2 Courtesy: Basic medical key.